Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfaflor is an ophthalmic combination drug containing betamethasone (a corticosteroid), naphazoline (a vasoconstrictor), and tetracycline (a broad-spectrum antibiotic). Developed by Alfa Intes, it is approved in Italy as eye drops for the treatment of bacterial and non-bacterial (including allergic) conjunctivitis, dacryocystitis, dacryostenosis, blepharoconjunctivitis, eczematous dermatitis of the eyelids, and other ocular inflammations or infections susceptible to tetracycline. Betamethasone acts as an anti-inflammatory agent by activating the glucocorticoid receptor, naphazoline reduces ocular congestion and redness by stimulating alpha-adrenergic receptors to induce vasoconstriction, and tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alfaflor.